Background: Although most patients with Parkinson's disease (PD) show decreased cardiac (123)I-metaiodobenzylguanidine (MIBG) uptake, some exhibit normal uptake. We evaluated the clinical characteristics of such patients.
Methods: We enrolled 154 non-demented patients showing parkinsonism with normal cardiac MIBG uptake and had been clinically followed up during 29.9 ± 27.6 months. We defined the patients who did not fit the exclusion criteria for PD and demonstrated ≥ 30% reduction in the Unified Parkinson's Disease Rating Scale (UPDRS) motor score after anti-Parkinson agent administration as probable PD. We compared clinical characteristics and the cardiac MIBG heart-to-mediastinum (H/M) ratio between the probable PD group (N=37) and other groups (N=117).
Results: The probable PD group showed significantly higher UPDRS motor scores and greater incidence of tremor/rigidity than those of other groups. In addition, they showed a significantly lower cardiac MIBG H/M ratio in the delayed phase (delayed, p<0.0001). Washout-rate (WR) was significantly higher in probable PD cases (p<0.0001). Among 16 probable PD patients undergoing serial cardiac MIBG scintigraphy, the delayed phase cardiac MIBG H/M ratio showed a significant decrease and WR significantly increased during follow-up periods.
Conclusions: An increase in WR and lower delayed phase cardiac MIBG uptake were found to be characteristics of such patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jns.2015.10.059 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Diagnostic Efficacy of Iodo-Metaiodobenzylguanidine SPECT/CT in Cardiac vs. Neurological Diseases: A Comparative Study of Arrhythmogenic Right Ventricular Cardiomyopathy and α-Synucleinopathies.
Diagnostics (Basel)
December 2024
Department of Medicine I, University Hospital Munich, Ludwig-Maximilians-University, 81377 Munich, Germany.
: Iodo-metaiodobenzylguanidine single photon emission computed tomography/computed tomography (I-MIBG SPECT/CT) is used to evaluate the cardiac sympathetic nervous system in cardiac diseases such as arrhythmogenic right ventricular cardiomyopathy (ARVC) and α-synucleinopathies such as Parkinson's diseases. A common feature of these diseases is denervation. We aimed to compare quantitative and semi-quantitative cardiac sympathetic innervation using I-MIBG imaging of ARVC and α-synucleinopathies.
View Article and Find Full Text PDFIodine-123 Metaiodobenzylguanidine (I-123 MIBG) in Clinical Applications: A Comprehensive Review.
Pharmaceuticals (Basel)
November 2024
Department of Obstetrics and Gynecology, College of Medicine, National Taiwan University, Taipei 100233, Taiwan.
Iodine-123 metaiodobenzylguanidine (I-123 MIBG) is a crucial radiopharmaceutical widely used in nuclear medicine for its diagnostic capabilities in both cardiology and oncology. This review aims to present a comprehensive evaluation of the clinical applications of I-123 MIBG, focusing on its use in diagnosing and managing various diseases. In cardiology, I-123 MIBG has proven invaluable in assessing cardiac sympathetic innervation, particularly in patients with heart failure, where it provides prognostic information that guides treatment strategies.
View Article and Find Full Text PDFGastric emptying time and its correlation with cardiac MIBG in body-first and brain-first subtype Parkinson's disease.
J Neurol
December 2024
Department of Neurology, Ajou University School of Medicine, Suwon, Republic of Korea.
Introduction: Recently, "body-first" and "brain-first" subtype in Parkinson's disease (PD) was proposed based on the propagation of α-synuclein. In isolated RBD considered as a premotor stage of body-first PD, α-synuclein was supposed to originate in the enteric nervous system and spreads via autonomic nervous system. Therefore, we hypothesized that body-first PD is more likely to have a delayed gastric emptying time and reduced cardiac sympathetic denervation.
View Article and Find Full Text PDFComparison of MIBG uptake in the major salivary glands between Lewy body disease and progressive supranuclear palsy.
Clin Park Relat Disord
November 2024
Department of Neurology, Toho University Faculty of Medicine, Tokyo, Japan.
Introduction: Cardiac sympathetic denervation is specific to Lewy body disease (LBD). In Parkinson's disease (PD), sympathetic denervation in the major salivary glands (parotid glands [PG] and submandibular glands [SMG]) has been demonstrated by I-metaiodobenzylguanidine (MIBG) scintigraphy. We compared sympathetic denervation in the MSG between PD, dementia with Lewy bodies (DLB), and progressive supranuclear palsy (PSP).
View Article and Find Full Text PDFEffectiveness of Lee Silverman Voice Treatment (LSVT-LOUD) in Parkinsonian-Type Multiple System Atrophy (MSA-P): A Case Report.
Cureus
November 2024
Graduate School of Health Science, Fukui Health Science University, Fukui, JPN.
Article Synopsis
- A 73-year-old patient with Parkinsonian-type multiple system atrophy (MSA-P) experienced motor symptoms, including gait disturbances and swallowing difficulties, prompting medical evaluation.
- Brain imaging and diagnostic tests confirmed MSA-P, but traditional Parkinson’s treatments showed minimal effectiveness as the patient's condition worsened.
- After undergoing Lee Silverman Voice Treatment (LSVT-LOUD) at age 75, the patient showed significant improvements in speech volume, swallowing abilities, and cognitive function, indicating potential benefits of LSVT-LOUD for patients with MSA-P.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!